Abderrahim Oukessou

Title: Abderrahim Oukessou: Innovator in Cancer Treatment

Introduction

Abderrahim Oukessou is a notable inventor based in Skillman, NJ (US). He has made significant contributions to the field of cancer treatment, particularly in the area of non-small cell lung cancer (NSCLC). His innovative approach combines chemotherapy with targeted immunotherapy.

Latest Patents

Oukessou holds a patent titled "Methods of treating NSCLC comprising administering platinum doublet chemotherapy followed by an anti-PD-1 antibody and an anti-CTLA-4 antibody." This patent outlines a method for treating patients afflicted with tumors derived from NSCLC. The method involves administering a combination of chemotherapy, an anti-PD-1 antibody or an anti-PD-L1 antibody, and an anti-CTLA-4 antibody. Notably, the chemotherapy is administered for a period shorter than the standard treatment duration. He has 1 patent to his name.

Career Highlights

Abderrahim Oukessou is currently employed at Bristol-Myers Squibb Company, a leading biopharmaceutical company. His work focuses on developing innovative therapies that improve patient outcomes in oncology.

Collaborations

Oukessou collaborates with talented professionals in his field, including Sabine Maier and Nicholas Allan Botwood. Their combined expertise contributes to advancing cancer treatment methodologies.

Conclusion

Abderrahim Oukessou is a pioneering inventor whose work in cancer treatment is making a significant impact. His innovative methods and collaborations are paving the way for improved therapies for patients with non-small cell lung cancer.